X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
MDG1015 is a first-in-class, third generation TCR-T therapy targeting NY-ESO-1/ LAGE-1a. It is being developed for gastric cancer, ovarian cancer and two types of soft tissue sarcomas, myxoid/round cell liposarcoma and synovial sarcoma.
Lead Product(s): MDG1015
Therapeutic Area: Oncology Product Name: MDG1015
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2024
Details:
Under the agreement, AGC Biologics is providing autologous production for MDG1015, a third generation TCR-T therapy, focused on the treatment of solid cancers, supporting Medigene’s IND filing and clinical trials.
Lead Product(s): MDG1015,PD1-41BB
Therapeutic Area: Oncology Product Name: MDG1015
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Recipient: AGC Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 25, 2023
Details:
MDG2011, a T cell receptor engineered T cell (TCR-T) therapy targeting KRAS (Kirsten rat sarcoma viral oncogene homologue) G12V with HLA-A*11 and being developed in combination with the Company’s PD1-41BB costimulatory switch protein (CSP) technology.
Lead Product(s): MDG2011
Therapeutic Area: Oncology Product Name: MDG2011
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2023
Details:
The patent issued by the Japan Patent Office protecting its PD1-41BB switch receptor. Medigene's PD1-41BB costimulatory switch receptor technology was developed by its partner Helmholtz Munich and is exclusively licensed to Medigene.
Lead Product(s): TCR-T-based Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 22, 2023
Details:
Under the agreement, Medigene accelerates the expansion of its end-to-end platform of multiple, combinable, exclusive and proprietary technologies with the potential to create best-in-class T cell receptor engineered T cell (TCR-T) therapies for patients with solid tumors.
Lead Product(s): TCR-T-based Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Recipient: Helmholtz Zentrum München
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 02, 2023
Details:
The companies will collaborate to evaluate the potential of Medigene’s proprietary T cell receptors (TCRs) to be used in new cell constructs for the treatment of solid tumors in T cell-based Therapy.
Lead Product(s): T cell-based Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: National Cancer Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 03, 2023
Details:
MDG1011 is a TCR-T immunotherapy directed against the tumor antigen PRAME and was manufactured to be administered in a single intravenous dose to patients suffering from relapsed or refractory acute myeloid leukemia, myelodysplastic syndrome or multiple myeloma.
Lead Product(s): MDG1011
Therapeutic Area: Oncology Product Name: MDG1011
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2023
Details:
The program is designed for the development of 2seventy bio’s MAGE-A4 program which employs a highly potent TCR discovered in collaboration with Medigene’s proprietary end-to-end technology platform. The program is designed to develop TCR-based therapies.
Lead Product(s): TCR-based Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: 2Seventy Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 18, 2023
Details:
BioNTech will acquire Medigene’s next generation preclinical TCR program, which combines TCR-4 of Medigene’s MDG10XX program targeting PRAME with Medigene’s proprietary PD1-41BB switch receptor technology.
Lead Product(s): TCR Immunotherapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: BioNTech
Deal Size: Undisclosed Upfront Cash: $29.1 million
Deal Type: Collaboration February 21, 2022
Details:
The Phase I study of MDG1021 will be initiated at the Leiden University Medical Center (LUMC), the Netherlands, and will enroll patients suffering from relapsed or persistent blood cancers after allogeneic (non-self) hematopoietic stem cell transplantation
Lead Product(s): MDG1021
Therapeutic Area: Oncology Product Name: MDG1021
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
